Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experience

Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experience

Background: Advanced stage ovarian carcinoma has a poor prognosis with recurrence rates of over 80%, 5-year survival of 36–45%, and limited response to standard therapy. Pembrolizumab and lenvatinib are FDA approved for treatment of microsatellite stable (MSS)/mismatch repair proficient (pMMR) endom...

Full description

Saved in:
Bibliographic Details
Main Authors: Helen Toma, Rebeca Kelly, Chelsea Katz, Hannah Hong, Hannah Diasti, David P. Warshal, Lauren Krill
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Gynecologic Oncology Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578925001365
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items